Erlotinib in lung cancer: Molecular and clinical predictors of outcome

Article Abstract:

Tumor-biopsy samples from participants are used to investigate whether responsiveness to erlotinib and its impact on survival are associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations. Among patients with non-small-cell lung cancer who receive erlotinib, the presence of EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.

Author: Ming-Sound Tsao, Kamel-Reid, Suzanne, Squire, Jeremy, Keyue Ding, Sakurada, Akira, Cutz, Jean-Claude, Chang-Qi Zhu, Marrano, Paula, Whitehead, Marlo, Lorimer, Ian, Santos, Gilda da Cunha, Tong Zhang, Lagarde, Alain, Pater, Joseph, Ni Liu, Richardson, Frank, Sheperd, Frances A., Daneshmand, Manijeh, Seumour, Lesley
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
Science & research, Research, Patient outcomes, Genetic aspects, Lung cancer

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

Article Abstract:

A study was conducted to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. The result showed that adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs ease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.

Author: Ming-Sound Tsao, Johnson, David, Cormier, Yvon, Ayoub, Joseph, Johnston, Michael, Graham, Barbara Wood, Winton, Timothy, Livingston, Robert, Rigas, James, Goss, Glenwood, Butts, Charles, Vallieres, Eric, Fry, Willard, Inculet, Richard, Bethune, Drew, Kesler, Kenneth, Keyue Ding, Seymour, Lesley, Demmy, Todd, Shepherd, Frances
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
United Kingdom, Drug therapy, Dosage and administration, Cisplatin, Vinorelbine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Erlotinib in previously treated non-small-cell lung cancer

Article Abstract:

A randomized, placebo-controlled, double-blind trial is conducted to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. The findings indicate that erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

Author: Seymour, Lesley, Shepherd, Frances A., Pereira, Jose Rodrigues, Ciuleanu, Tudor, Eng Huat Tan, Hirsh, Vera, Thongprasert, Sumitra, Ooten, Maximiliano van, Bezjak, Andrea, Campos, Daniel, Dediu, Mircea, Clark, Gary, Maoleekoonpiroj, Savitree, Findlay, Brian, Santabarbara, Pedro, Smylie, Michael, Dongsheng Tu, Martins, Renato, Johnston, Dianne
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
Health aspects, Clinical trials

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Care and treatment, New England, Epidermal growth factor receptors, Lung cancer, Non-small cell, Non-small cell lung cancer
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.